A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma Raz DJ et al. - This multigene assay predicts overall and disease-free survival significantly better than clinical stage and tumor size in patients with early stage lung adenocarcinoma and performs especially well in patients with stage I disease. Prospective clinical trials are needed to determine whether high-risk patients with stage I disease benefit from adjuvant chemotherapy. [more...]
